Global Amlodipine Besylate API Prices Edge Higher On Worries Over Tight Supply

Global Amlodipine Besylate API prices continued to edge up in September because of tight product supply ahead of the low production activities in the manufacturing plants, on the one hand, and the escalating demand in the end-user sector, on the other.

The prices of Amlodipine Besylate API in China increased to 2.1% in the mid of September due to the shortage of inventories in the domestic market hit last month on the back of insufficient electricity supplies in the plant. The production of Amlodipine Besylate API is low as some industries in China were forced to reduce their working hours or even shut down entirely to comply with energy constraints. On the other hand, the market transactions are active on the back of increased demand from end-user pharmaceuticals, further supporting the cost hike.

Meanwhile, the USA domestic market is also experiencing a shortage of Amlodipine Besylate API due to a disrupted supply chain from China on the back of a power crunch, further pushing the Amlodipine Besylate API prices by 4.6% in the last month values. Moreover, many end-user industries found themselves facing significant delays in obtaining necessary inventories for the production of finished drug and their sales. Regardless of the low imports, the traders in the US market experienced pressure to cater to overall demand from downstream industries.

In Germany, comparable market fundamentals, including hindered supplies and consistent demand, have been observed for Amlodipine Besylate API. Also, water levels on the Rhine in Germany continue to fall in hot weather, resulting in higher shipping costs and disruption in trade activities. The prices have surged to 6.2% for Amlodipine Besylate API in September.

According to ChemAnalyst, the Amlodipine Besylate API prices may decrease next month due to ease in trading activities and steady demand from end-user industries.